Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
domenica, ottobre 25
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Arcutis Biotherapeutics Inc
ARQT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$31.20
-1.00
-3.11%
Ult. Agg.: Oct 23, 4:37 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 10 giorni da adesso in mer nov 4th, dopo la chiusura del mercato
Arcutis Biotherapeutics Financials
Arcutis Biotherapeutics (ARQT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.03 by 266.67 percent. This is a 184.62 percent increase over losses of $(0.13) per
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Arcutis Biotherapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $105.398M Beat $101.261M Estimate
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 55 percent increase over losses of $(0.20) per share
Benzinga Newsdesk
PRO
Arcutis Biotherapeutics Q4 EPS $0.13 Beats $0.10 Estimate, Sales $129.503M Beat $113.055M Estimate
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.10 by 32.65 percent. This is a 244.44 percent increase over losses of $(0.09) per share
Benzinga Newsdesk
Earnings Scheduled For February 25, 2026
Benzinga Insights
Preview: Arcutis Biotherapeutics's Earnings
Benzinga Insights
